FMP

FMP

Enter

JNCE - Jounce Therapeutics,...

photo-url-https://financialmodelingprep.com/image-stock/JNCE.png

Jounce Therapeutics, Inc.

JNCE

NASDAQ

Inactive Equity

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

1.88 USD

0 (0%)

Earnings

We are unable to load the chart at this time.

fmp-logo

Dividends

We are unable to load the chart at this time.

fmp-logo

Splits

We are unable to load the chart at this time.

fmp-logo

From:

To:

Date

Revenue

Earnings

Estimated Earnings

Surprise

No data found!

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep